- Fund II reaches first shut and is already deploying capital
- Fund II leads Automata Technologies’ Series C, alongside world science and expertise chief Danaher
- Fund II builds on a primary fund absolutely deployed throughout 14 excessive development life sciences firms
NEW YORK–(BUSINESS WIRE)–Eckuity Capital, a North American healthcare development fairness agency, right now introduced the primary shut of Eckuity Capital Fund II and the fund’s inaugural funding, main the Series C of Automata Technologies alongside Danaher, a world science and expertise chief.
Automata makes use of synthetic intelligence to automate laboratory operations for all times sciences and diagnostics organisations, work that has lengthy been handbook, gradual, and exhausting to scale. Backing from Eckuity and Danaher locations the corporate on the middle of how synthetic intelligence is altering scientific work.
Eckuity Capital Fund II extends a technique confirmed in Eckuity’s first fund, which is absolutely deployed throughout 14 firms, investing in commercial-stage life sciences firms and combining capital with the industrial assist to scale them. With its first shut full and capital already at work, Eckuity will hold constructing the Fund II portfolio via the yr.
Eckuity has additionally strengthened its funding group, welcoming Paul Enever and Alejandro Sanchez as Partners. Enever, a former McKinsey companion with 25 years in medical expertise, serves on a number of boards together with GT Medical Technologies and Magnolia Medical Technologies, with previous exits together with Cardiva Medical to Haemonetics. Sanchez, a former McKinsey companion and co-founder of Hermes Growth Partners, sits on the board of PreludeDx, with previous exits together with Biotheranostics to Hologic.
“Healthcare will change more in the next decade than it has in a generation, and the firms that matter will be the ones turning artificial intelligence into tools clinicians and scientists actually use,” stated Youssef Sebban, Founder and Managing Partner of Eckuity Capital. “We built Eckuity to back those companies at the commercial stage, where the change becomes real. Opening Fund II with our first investment in Automata, alongside Danaher, is the standard we intend to set. And we are only getting started.”
“Automating the lab is one of the highest-leverage problems in science, and solving it takes partners who understand both the technology and the path to commercial scale,” stated Mostafa ElSayed, CEO of Automata Technologies. “Eckuity led our Series C because they understood exactly what we are building. With Eckuity and Danaher behind us, we can bring AI into the lab at a pace the field has not seen.”
About Eckuity Capital
Eckuity Capital is a healthcare development fairness agency investing in commercial-stage firms throughout North America and Western Europe, spanning medical expertise, diagnostics, and tech-enabled healthcare companies. Beyond capital, the agency supplies the industrial assist its firms have to scale. Founded in 2021, Eckuity operates from New York, London, and Miami. For extra data, go to www.eckuity.com.
This press launch is for informational functions solely and doesn’t represent a suggestion to promote or the solicitation of a suggestion to purchase any safety or curiosity in any fund managed by Eckuity Capital. Any such supply will probably be made solely via definitive providing paperwork and to eligible buyers. Statements relating to future occasions or expectations are forward-looking and topic to dangers and uncertainties.
Contacts
Media Contact
Eckuity Capital
Ryan Green, Head of Capital Formation and Investor Relations
[email protected] | +1 (973) 229-7859